title: Hyperinsulinemia potentiates airway responsiveness to parasympathetic nerve stimulation in obese rats.
abstract: Obesity is a substantial risk factor for developing asthma, but the molecular mechanisms underlying this relationship are unclear. We tested the role of insulin in airway responsiveness to nerve stimulation using rats genetically prone or resistant to diet-induced obesity. Airway response to vagus nerve stimulation and airway M2 and M3 muscarinic receptor function were measured in obese-prone and -resistant rats with high or low circulating insulin. The effects of insulin on nerve-mediated human airway smooth muscle contraction and human M2 muscarinic receptor function were tested in vitro. Our data show that increased vagally mediated bronchoconstriction in obesity is associated with hyperinsulinemia and loss of inhibitory M2 muscarinic receptor function on parasympathetic nerves. Obesity did not induce airway inflammation or increase airway wall thickness. Smooth muscle contraction to acetylcholine was not increased, indicating that hyperresponsiveness is mediated at the level of airway nerves. Reducing serum insulin with streptozotocin protected neuronal M2 receptor function and prevented airway hyperresponsiveness to vagus nerve stimulation in obese rats. Replacing insulin restored dysfunction of neuronal M2 receptors and airway hyperresponsiveness to vagus nerve stimulation in streptozotocin-treated obese rats. Treatment with insulin caused loss of M2 receptor function, resulting in airway hyperresponsiveness to vagus nerve stimulation in obese-resistant rats, and inhibited human neuronal M2 receptor function in vitro. This study shows that it is not obesity per se but hyperinsulinemia accompanying obesity that potentiates vagally induced bronchoconstriction by inhibiting neuronal M2 muscarinic receptors and increasing acetylcholine release from airway parasympathetic nerves.
authors.affiliation: Pulmonary and Critical Care Medicine, Oregon Health and Science University, Portland, Oregon.
authors.forename: Zhenying
authors.initials: Z
authors.lastname: Nie
authors.forename: David B
authors.initials: DB
authors.lastname: Jacoby
authors.forename: Allison D
authors.initials: AD
authors.lastname: Fryer
mesh_terms: D000109:Acetylcholine / Q000378:metabolism / Q000494:pharmacology; D000818:Animals; D001249:Asthma / Q000209:etiology* / Q000378:metabolism / Q000503:physiopathology; D016535:Bronchial Hyperreactivity / Q000209:etiology* / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control; D016084:Bronchoconstriction / Q000187:drug effects; D016085:Bronchoconstrictor Agents / Q000494:pharmacology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation; D006801:Humans; D006946:Hyperinsulinism / Q000150:complications* / Q000378:metabolism / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007328:Insulin / Q000378:metabolism / Q000494:pharmacology; D008168:Lung / Q000294:innervation*; D018721:Muscarinic Agonists / Q000494:pharmacology; D009433:Neural Inhibition; D009765:Obesity / Q000150:complications* / Q000378:metabolism / Q000503:physiopathology; D051381:Rats; D043585:Receptor, Muscarinic M2 / Q000378:metabolism; D043587:Receptor, Muscarinic M3 / Q000378:metabolism; D013311:Streptozocin / Q000494:pharmacology; D013997:Time Factors; D014630:Vagus Nerve / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*
chemical_list: D016085:Bronchoconstrictor Agents; D007004:Hypoglycemic Agents; D007328:Insulin; D018721:Muscarinic Agonists; D043585:Receptor, Muscarinic M2; D043587:Receptor, Muscarinic M3; D013311:Streptozocin; D000109:Acetylcholine
keywords: airway responsiveness; asthma; hyperinsulinemia; neural M2 muscarinic receptor; obesity